Unique Gut Bacteria with Strong Therapeutic Benefit Potential
Since its discovery in 2012, an increasing body of evidence have shown that the Christensenellaceae family plays a major role in the development of a healthy gut microbiome and is missing in many chronically ill patients.
YSOPIA validated the potential of Christensenella for the treatment of obesity and associated metabolic disorders, as well as for Crohn’s disease in a series of foundational proof of concept studies. The seminal work conducted by YSOPIA demonstrating in vivo that our clinical candidate Xla1 limits body weight gain and normalizes several metabolic markers was published in Cells (Mazier et al. 2021).
LNC Therapeutics becomes
YSOPIA bioscience
« This new name, YSOPIA Bioscience, symbolizes the major success of our teams in advancing to the clinic, in line with our ambition to become a major player in developing ground-breaking therapies based on the gut microbiome potential »
Dr Georges RAWADI, CEO
~ more ABOUT IT